GSK melanoma drug combination wins accelerated U.S. approval

January 9, 2014 8:16 AM

10 0

GSK melanoma drug combination wins accelerated U.S. approval

LONDON (Reuters) - A combination treatment from GlaxoSmithKline for melanoma, the deadliest form of skin cancer, has won accelerated approval from U.S. regulators.

The green light for the combined use of Tafinlar, also known as dabrafenib, and Mekinist, or trametinib, from the Food and Drug Administration (FDA) is the first of its kind for a form of the disease with a specific genetic profile.

Read more

To category page

Loading...